Induced pluripotent stem cell-derived mesenchymal stem cells prolong hind limb survival in a rat vascularized composite allotransplantation model.
Journal
Microsurgery
ISSN: 1098-2752
Titre abrégé: Microsurgery
Pays: United States
ID NLM: 8309230
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
25
07
2019
revised:
13
08
2019
accepted:
16
08
2019
pubmed:
1
9
2019
medline:
28
4
2020
entrez:
1
9
2019
Statut:
ppublish
Résumé
The reduction of systemic immunosuppressive agents is essential for the expansion of vascularized composite allotransplantation (VCA) in a clinical setting. The purpose of this study is to compare human-induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs) with four other types of mesenchymal stem cells (human bone marrow-derived MSCs [BMMSCs], human adipose-derived MSCs [ADMSCs], rat BMMSCs, and rat ADMSCs) in vitro, and to investigate the in vivo immunomodulatory effect of iMSCs in a rat VCA model. One Brown Norway (BN) rat, 2 Lewis (LEW) rats, and 1 Wistar rat were used in the mixed lymphocyte reaction (MLR), and 9 BN rats and 3 LEW rats (for donors), and 24 LEW rats (for recipients) were used in the VCA model. The abovementioned five types of MSCs were imaged to examine their morphology and were also tested for suppressor function using a MLR. The 24 recipient LEW rats were divided randomly into four groups, and subjected to orthotopic hind limb transplantation. The three control groups were the Iso group, in which transplantation was performed on from three to six LEW rats without immunosuppressive treatment (n = 6); the FK group, in which transplantation was performed from BN rats to LEW rats and recipient rats were treated with tacrolimus alone (FK 506, 0.2 mg/kg, days 0-6 postoperatively, intraperitoneally) (n = 6); and the UT group, in which transplantation was performed from BN rats to LEW rats without any immunosuppressive treatment (n = 6). The experimental group was the iMSC group, in which transplantation was performed from BN rats to LEW rats and recipient rats were treated with tacrolimus (FK 506, 0.2 mg/kg, days 0-6 postoperatively, intraperitoneally) and injected with iMSCs (2 × 10 The size of adherent and trypsinized iMSCs was 67.5 ± 8.7 and 9.5 ± 1.1 μm, respectively, which was the smallest among the five types of MSCs (p < .01). The absorbance in MLR was significantly smaller with rat ADMSCs (p = .0001), human iMSCs (p = .0006), rat BMMSCs (p = .0014), human ADMSCs (p = .0039), and human BMMSCs (p = .1191) compared to without MSCs. In vivo, iMSC treatment prolonged hind limb survival up to 12.7 days in macroscopic appearance, which is significantly longer than that of the FK group (p < .01). Histology of the skin and muscle biopsy revealed that mononuclear cell infiltration was significantly reduced by iMSC injection (p < .01). iMSC treatment also affected proinflammatory cytokines (interferon-gamma (IFNγ) and tumor necrosis factor α (TNFα)) and the anti-inflammatory cytokine (interleukin-10 (IL-10)) of the recipient plasma. The IFNγ levels at Δ14 and the TNFα levels at Δ14 and Δ17 of the iMSC group were significantly lower than those of the FK group (p = .0226, .0004, and .004, respectively). The IL-10 levels at Δ10 and Δ14 of the iMSC group were significantly higher than those of the FK group (p = .0013 and .0374, respectively). iMSCs induce T cell hyporesponsiveness to prolong hind limb survival in a rat VCA model. This immunomodulatory property against acute rejection could provide one of the promising strategies capable of enabling the toxicities of immunosuppressants to be avoided in clinical settings.
Sections du résumé
BACKGROUND
BACKGROUND
The reduction of systemic immunosuppressive agents is essential for the expansion of vascularized composite allotransplantation (VCA) in a clinical setting. The purpose of this study is to compare human-induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs) with four other types of mesenchymal stem cells (human bone marrow-derived MSCs [BMMSCs], human adipose-derived MSCs [ADMSCs], rat BMMSCs, and rat ADMSCs) in vitro, and to investigate the in vivo immunomodulatory effect of iMSCs in a rat VCA model.
MATERIALS AND METHODS
METHODS
One Brown Norway (BN) rat, 2 Lewis (LEW) rats, and 1 Wistar rat were used in the mixed lymphocyte reaction (MLR), and 9 BN rats and 3 LEW rats (for donors), and 24 LEW rats (for recipients) were used in the VCA model. The abovementioned five types of MSCs were imaged to examine their morphology and were also tested for suppressor function using a MLR. The 24 recipient LEW rats were divided randomly into four groups, and subjected to orthotopic hind limb transplantation. The three control groups were the Iso group, in which transplantation was performed on from three to six LEW rats without immunosuppressive treatment (n = 6); the FK group, in which transplantation was performed from BN rats to LEW rats and recipient rats were treated with tacrolimus alone (FK 506, 0.2 mg/kg, days 0-6 postoperatively, intraperitoneally) (n = 6); and the UT group, in which transplantation was performed from BN rats to LEW rats without any immunosuppressive treatment (n = 6). The experimental group was the iMSC group, in which transplantation was performed from BN rats to LEW rats and recipient rats were treated with tacrolimus (FK 506, 0.2 mg/kg, days 0-6 postoperatively, intraperitoneally) and injected with iMSCs (2 × 10
RESULTS
RESULTS
The size of adherent and trypsinized iMSCs was 67.5 ± 8.7 and 9.5 ± 1.1 μm, respectively, which was the smallest among the five types of MSCs (p < .01). The absorbance in MLR was significantly smaller with rat ADMSCs (p = .0001), human iMSCs (p = .0006), rat BMMSCs (p = .0014), human ADMSCs (p = .0039), and human BMMSCs (p = .1191) compared to without MSCs. In vivo, iMSC treatment prolonged hind limb survival up to 12.7 days in macroscopic appearance, which is significantly longer than that of the FK group (p < .01). Histology of the skin and muscle biopsy revealed that mononuclear cell infiltration was significantly reduced by iMSC injection (p < .01). iMSC treatment also affected proinflammatory cytokines (interferon-gamma (IFNγ) and tumor necrosis factor α (TNFα)) and the anti-inflammatory cytokine (interleukin-10 (IL-10)) of the recipient plasma. The IFNγ levels at Δ14 and the TNFα levels at Δ14 and Δ17 of the iMSC group were significantly lower than those of the FK group (p = .0226, .0004, and .004, respectively). The IL-10 levels at Δ10 and Δ14 of the iMSC group were significantly higher than those of the FK group (p = .0013 and .0374, respectively).
CONCLUSIONS
CONCLUSIONS
iMSCs induce T cell hyporesponsiveness to prolong hind limb survival in a rat VCA model. This immunomodulatory property against acute rejection could provide one of the promising strategies capable of enabling the toxicities of immunosuppressants to be avoided in clinical settings.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
737-747Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Adamson, L. A., Huang, W. C., Breidenbach, W. C., Rahhal, D., Xu, H., Huang, Y., … Ildstad, S. T. (2007). A modified model of hindlimb osteomyocutaneous flap for the study of tolerance to composite tissue allografts. Microsurgery, 27(7), 630-636.
Cheng, H. Y., Ghetu, N., Huang, W. C., Wang, Y. L., Wallace, C. G., Wen, C. J., … Wei, F. C. (2014). Syngeneic adipose-derived stem cells with short-term immunosuppression induce vascularized composite allotransplantation tolerance in rats. Cytotherapy, 16(3), 369-380.
Chow, L., Johnson, V., Regan, D., Wheat, W., Webb, S., Koch, P., & Dow, S. (2017). Safety and immune regulatory properties of canine induced pluripotent stem cell-derived mesenchymal stem cells. Stem Cell Research, 25, 221-232.
Davis, T. A., Anam, K., Lazdun, Y., Gimble, J. M., & Elster, E. A. (2014). Adipose-derived stromal cells promote allograft tolerance induction. Stem Cells Translational Medicine, 3(12), 1444-1450.
Dubernard, J. M., Owen, E., Herzberg, G., Lanzetta, M., Martin, X., Kapila, H., … Hakim, N. S. (1999). Human hand allograft: Report on first 6 months. Lancet, 353, 1315-1320.
Fitzpatrick, E. B., Dehart, M. J., Brown, T. A., & Salgar, S. K. (2017). Mesenchymal stem cell therapy to promote limb transplant functional recovery. Microsurgery, 37(3), 222-234.
Fukuta, M., Nakai, Y., Kirino, K., Nakagawa, M., Sekiguchi, K., Nagata, S., … Toguchida, J. (2014). Derivation of mesenchymal stromal cells from pluripotent stem cells through a neural crest lineage using small molecule compounds with defined media. PLoS One, 9(12), e112291.
Heyes, R., Iarocci, A., Tchoukalova, Y., & Lott, D. G. (2016). Immunomodulatory role of mesenchymal stem cell therapy in vascularized composite allotransplantation. Journal of Transplantation, 6951693.
Ikeguchi, R., Kakinoki, R., Ohta, S., Oda, H., Yurie, H., Kaizawa, Y., … Matsuda, S. (2017). Recipient bone marrow-derived stromal cells prolong graft survival in a rat hind limb allotransplantation model. Microsurgery, 37(6), 632-640.
Ko, S. F., Chen, Y. T., Wallace, C. G., Chen, K. H., Sung, P. H., Cheng, B. C., … Yip, H. K. (2018). Inducible pluripotent stem cell-derived mesenchymal stem cell therapy effectively protected kidney from acute ischemia-reperfusion injury. American Journal of Translational Research, 10(10), 3053-3067.
Kuo, Y. R., Chen, C. C., Shih, H. S., Goto, S., Huang, C. W., Wang, C. T., … Wei, F. C. (2011). Prolongation of composite tissue allotransplant survival by treatment with bone marrow mesenchymal stem cells is correlated with T-cell regulation in a swine hind-limb model. Plastic and Reconstructive Surgery, 127(2), 569-579.
Lee, S. M., Lee, S. C., & Kim, S. J. (2014). Contribution of human adipose tissue-derived stem cells and the secretome to the skin allograft survival in mice. Journal of Surgical Research, 188(1), 280-289.
Lian, Q., Zhang, Y., Zhang, J., Zhang, H. K., Wu, X., Zhang, Y., … Tse, H. F. (2010). Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation, 121, 1113-1123.
Miura, Y., Thoburn, C. J., Bright, E. C., Chen, W., Nakao, S., & Hess, A. D. (2002). Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): Interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD. Blood, 100(7), 2650-2658.
Muramatsu, K., Kurokawa, Y., Kuriyama, R., Taguchi, T., & Bishop, A. T. (2005). Gradual graft-cell repopulation with recipient cells following vascularized bone and limb allotransplantation. Microsurgery, 25(8), 599-605.
Nakagawa, M., Taniguchi, Y., Senda, S., Takizawa, N., Ichisaka, T., Asano, K., … Yamanaka, S. (2014). A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells. Scientific Reports, 4, 3594.
Oceguera-Yanez, F., Kim, S., Matsumoto, T., Tan, G., Xiang, L., Hatani, T., … Woltjen, K. (2016). Engineering the AAVS1 locus for consistent and scalable transgene expression in human iPSCs and their differentiated derivatives. Methods, 101, 43-55.
Oda, H., Ikeguchi, R., Aoyama, T., Ohta, S., Noguchi, T., Kaizawa, Y., … Matsuda, S. (2019). Relative antigenicity of components in vascularized composite allotransplants: An experimental study of microRNAs expression in rat hind limb transplantation model. Microsurgery, 39(4), 340-348.
Oda, H., Ikeguchi, R., Yurie, H., Kaizawa, Y., Ohta, S., Yamamoto, K., … Matsuda, S. (2016). Plasma microRNAs are potential biomarkers of acute rejection after hindlimb transplantation in rats. Transplantion Direct, 2(11), e108.
Park, M. J., Kwok, S. K., Lee, S. H., Kim, E. K., Park, S. H., & Cho, M. L. (2015). Adipose tissue-derived mesenchymal stem cells induce expansion of interleukin-10-producing regulatory B cells and ameliorate autoimmunity in a murine model of systemic lupus erythematosus. Cell Transplantation, 24(11), 2367-2377.
Plock, J. A., Schnider, J. T., Zhang, W., Schweizer, R., Tsuji, W., Kostereva, N., … Gorantla, V. S. (2015). Adipose- and bone marrow- derived mesenchymal stem cells prolong graft survival in vascularized composite allotransplantation. Transplantation, 99, 1765-1773.
Quatra, F., Lowenberg, D. W., Buncke, H. J., Romeo, O. M., Brooks, D., Buntic, R. F., & Baxter-Lowe, L. A. (2006). Induction of tolerance to composite tissue allograft in a rat model. Microsurgery, 26(8), 573-578.
Radu, C. A., Kiefer, J., Gebhard, M. M., Bigdeli, A. K., Schmidt, V. J., Germann, G., … Kremer, T. (2016). Local administration of Mitomycin-C-treated peripheral blood mononuclear cells (PBMCs) prolongs allograft survival in vascularized composite allotransplantation. Microsurgery, 36(5), 417-425.
Ramirez, A., Cheng, H. Y., Lao, W. W., Wang, Y. L., Wen, C. J., Wallace, C. G., … Wei, F. C. (2014). A novel rat full-thickness hemi-abdominal wall/hindlimb osteomyocutaneous combined flap: Influence of allograft mass and vascularized bone marrow content on vascularized composite allograft survival. Transplant International, 27(9), 977-986.
Rasmusson, I., Ringden, O., Sundberg, B., & Blank, K. L. (2003). Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation, 76, 1208-1213.
Sacks, J. M., Kuo, Y. R., Taieb, A., Breitinger, J., Nguyen, V. T., Thomson, A. W., … Lee, W. P. A. (2008). Prolongation of composite tissue allograft survival by immature recipient dendritic cells pulsed with donor antigen and transient low-dose immunosuppression. Plastic and Reconstructive Surgery, 121(1), 37-49.
Shimizu, F., Okamoto, O., Katagiri, K., Fujiwara, S., & Wei, F. C. (2010). Prolonged ischemia increases severity of rejection in skin flap allotransplantation in rats. Microsurgery, 30(2), 132-137.
Shores, J. T., Malek, V., Lee, W. P. A., & Brandacher, G. (2017). Outcomes after hand and upper extremity transplantation. Journal of Materials Science. Materials in Medicine, 28, 72.
Siemionow, M., & Nasir, S. (2007). Chimerism and bone marrow based therapies in transplantation. Microsurgery, 27(5), 510-521.
Song, Y. X., Muramatsu, K., Kurokawa, Y., & Taguchi, T. (2005). Prolonged survival of rat hindlimb allografts following short-course FK506 and mycophenolate mofetil combination therapy. Microsurgery, 25(4), 353-359.
Tahvildari, M., Omoto, M., Chen, Y., Emami-Naeini, P., Inomata, T., Dohlman, T. H., … Dana, R. (2016). In vivo expansion of regulatory T cells by low-dose interleukin-2 treatment increases allograft survival in corneal transplantation. Transplantation, 100(3), 525-532.
Tse, W. T., Pendleton, J. D., Beyer, W. M., Egalka, M. C., & Guinan, E. C. (2003). Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation, 75, 389-397.
Tsuji, W., Schnider, J. T., McLaughlin, M. M., Schweizer, R., Zhang, W., Solari, M. G., … Gorantla, V. S. (2015). Effects of immunosuppressive drugs on viability and susceptibility of adipose- and bone marrow-derived mesenchymal stem cells. Frontiers in Immunology, 6, 131.
Wang, D., Sun, Y. Q., Gao, W. X., Fan, X. L., Shi, J. B., & Fu, Q. L. (2018). An in vitro and in vivo study of the effect of dexamethasone on immunoinhibitory function of induced pluripotent stem cell-derived mesenchymal stem cells. Cell Transplantation, 27(9), 1340-1351.
Wu, G. D., Nolta, J. A., Jin, Y. S., Barr, M. L., Yu, H., Starnes, V. A., & Cramer, D. V. (2003). Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation, 75(5), 679-685.
Yang, H., Aprecio, R. M., Zhou, X., Wang, Q., Zhang, W., Ding, Y., & Li, Y. (2014). Therapeutic effect of TSG-6 engineered iPSC-derived MSCs on experimental periodontitis in rats: A pilot study. PLoS One, 9(6), e100285.
Zhao, C., & Ikeya, M. (2018). Generation and applications of induced pluripotent stem cell-derived mesenchymal stem cells. Stem Cells International, 9601623.